A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.

Inclusion Criteria:

• Subjects who fully understood this trial and voluntarily signed the informed consentform;
• Men or women ≥ 18 years old;
• ECOG Performance Status (PS) 0 or 1;
• Life expectancy > 3 months.

Exclusion Criteria:

• Received any treatment with inhibitors against KRAS G12C mutation at any time, e.g.,AMG 510, MRTX 849, etc.;
• Patients requiring medications that can potentially prolong QTc interval;
• Other conditions that the investigator considers to be unsuitable for participation inthis study.